Comparison
Semaglutide vs tirzepatide: structure, receptors and the literature
Two long-acting incretin-based peptides with different designs and different receptor targets. This page compares their structures, identity values and the published research, and leaves the clinical results to the primary papers.
The short version
Semaglutide is an analogue of human GLP-1 that acts on the GLP-1 receptor. Tirzepatide is a different peptide that acts on both the GIP receptor and the GLP-1 receptor. Both carry a fatty-acid side chain on a lysine; for semaglutide, the published design work describes that side chain as the feature that raises albumin affinity and gives a long duration of action. Both are in the GLP-1 and incretin research peptide group in our catalog; the retatrutide vs tirzepatide page covers the third receptor, glucagon, and the CagriSema page covers semaglutide combined with an amylin analogue.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Receptor targets | GLP-1 receptor (described as a selective GLP-1 receptor agonist; Frías et al., 2021) | GIP receptor and GLP-1 receptor (dual agonist; Willard et al., 2020) |
| Design | Analogue of human GLP-1 with Aib at position 8 and Arg at position 34, derivatised at lysine 26 with a fatty-acid moiety (Lau et al., 2015) | Linear 39-residue peptide carrying a C20 fatty diacid moiety on a lysine side chain through a linker (PubChem record; sequence not reproduced here) |
| Formula (PubChem) | C187H291N45O59 | C225H348N48O68 |
| Average mass computed from the formula | 4113.6 Da (PubChem lists about 4114 g/mol) | 4813.5 Da (PubChem lists about 4813 g/mol) |
| Expected [M+4H]4+ / [M+5H]5+ / [M+6H]6+ | 1029.4 / 823.7 / 686.6 | 1204.4 / 963.7 / 803.3 |
| Catalog page | Semaglutide | Tirzepatide |
Semaglutide: a protracted GLP-1 analogue
Lau et al. (2015) describe the design goal as a once-weekly GLP-1 analogue, reached by raising albumin affinity and securing full stability against metabolic degradation. The fatty-acid moiety and the chemistry linking it to the peptide were the key features for albumin affinity and GLP-1 receptor potency. Semaglutide has two amino acid substitutions compared with human GLP-1 (Aib at position 8 and Arg at position 34) and is derivatised at lysine 26. The paper reports a GLP-1 receptor affinity of 0.38 ± 0.06 nM, three-fold lower than liraglutide's, with higher albumin affinity, and a plasma half-life of 46.1 hours in mini-pigs after intravenous administration. Knudsen and Lau (2019) review the discovery of liraglutide and semaglutide, including how fatty acid and linker combinations were optimised for albumin binding while keeping receptor potency.
Tirzepatide: an imbalanced, biased dual agonist
Willard et al. (2020) calculated receptor occupancy and report a greater degree of engagement for the GIP receptor than for the GLP-1 receptor, which they call an imbalanced mechanism of action. In signalling studies they report that tirzepatide mimics native GIP at the GIP receptor but is biased at the GLP-1 receptor toward cAMP generation over β-arrestin recruitment, with a weaker ability to drive GLP-1 receptor internalisation than GLP-1. In primary islets, β-arrestin1 limited the insulin response to GLP-1 but not to GIP or tirzepatide. These are findings from cell and islet experiments.
How the trials were designed
Three published phase 3 trials are useful for comparing study design. This section describes design only; the results are in the papers.
- SURPASS-2 (Frías et al., 2021). Open-label, 40-week, phase 3, in people with type 2 diabetes. 1879 participants were randomised 1:1:1:1 to three dose levels of tirzepatide or one dose level of semaglutide. The primary endpoint was the change in glycated haemoglobin from baseline to 40 weeks. This is the direct head-to-head comparison.
- STEP 1 (Wilding et al., 2021). Double-blind, 68 weeks, 1961 adults with obesity or overweight with a weight-related condition and without diabetes, randomised 2:1 to semaglutide or placebo plus lifestyle intervention. Coprimary endpoints were the percentage change in body weight and a weight reduction of at least 5%.
- SURMOUNT-1 (Jastreboff et al., 2022). Phase 3, double-blind, 72 weeks including a 20-week dose-escalation period, 2539 adults with the same eligibility pattern, randomised 1:1:1:1 to three dose levels of tirzepatide or placebo, with the same coprimary endpoints.
Because the three trials enrolled different populations and ran for different lengths, their results are not interchangeable. The head-to-head trial is the one designed to compare the two molecules.
Identity and mass spectrometry
Both molecules are large enough that electrospray mass spectrometry shows a series of multiply charged ions rather than a single [M+H]+ peak, which is why the table above lists the 4+, 5+ and 6+ values computed from the formulas. A batch result should show a charge series consistent with the average mass, usually after deconvolution. The fatty-acid side chain and the non-standard residue (Aib) both change the mass and the chromatographic behaviour compared with an unmodified peptide; peptide modifications explained covers the notation, and checking the mass spectrometry on a COA yourself shows the arithmetic. For how much of a vial is peptide at all, see peptide purity vs peptide content.
Catalog and tools
- Semaglutide research peptide: sizes, prices, data
- Tirzepatide research peptide: sizes, prices, data
- Semaglutide reconstitution calculator
- Tirzepatide reconstitution calculator
- All GLP-1 and incretin research peptides
References
- Lau J, Bloch P, Schäffer L, et al. (2015). Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem 58:7370-80. PubMed 26308095 · DOI
- Knudsen LB, Lau J (2019). The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne) 10:155. PubMed 31031702 · DOI
- Willard FS, Douros JD, Gabe MB, et al. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 5. PubMed 32730231 · DOI
- Frías JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 385:503-515. PubMed 34170647 · DOI
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 384:989-1002. PubMed 33567185 · DOI
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 387:205-216. PubMed 35658024 · DOI
Frequently asked questions
Which receptors do semaglutide and tirzepatide act on?
Semaglutide is described as a selective GLP-1 receptor agonist. Tirzepatide is a dual agonist of the GIP receptor and the GLP-1 receptor (Willard et al., 2020; Frías et al., 2021).
How do the two molecules differ in structure?
Semaglutide is human GLP-1 with two substitutions (Aib at position 8, Arg at position 34) and a fatty-acid derivatisation at lysine 26 (Lau et al., 2015). Tirzepatide is a different 39-residue linear peptide with a C20 fatty diacid on a lysine side chain.
What formulas do they have?
PubChem lists semaglutide as C187H291N45O59 (about 4114 g/mol) and tirzepatide as C225H348N48O68 (about 4813 g/mol).
What was the head-to-head trial design?
SURPASS-2 was an open-label, 40-week, phase 3 trial in people with type 2 diabetes. 1879 participants were randomised 1:1:1:1 to three dose levels of tirzepatide or one dose level of semaglutide, and the primary endpoint was the change in glycated haemoglobin at 40 weeks.